200
OGI: Germany is a great country to do business for a few reasons, and Alpha offers us an entry point into that country. Alpha has a GMP lab in the country; we can export trim and dried flower to their facility where it can be converted into cannabis oil and distributed to German patients.
CCIM: What is your expected production (dry and oil) for your business lines (Edison, ANKR, Trailer Park Buds)? How will you ensure your medical patients come first?
OGI: Organic production will make up a small percentage of our production. With the other brands, it’s a perpetual process of reviewing what is being demanded and adjusting what is being produced. Any plan must be able to be changed as quickly as possible as is the case for most things in this new, ever-changing industry.
CCIM: One of the amendments to Bill C-45 by the Senate was to allow for THC limits to be placed. One can appreciate the logic in doing so particularly at the onset and potency limits already exist to a degree in alcohol for example. Some believe doing so would safeguard the medical stream because higher THC strains would fall within the medical classifications – an analogy would be prescription strength vs. non-prescription strength. Hypothetically, if a limit was placed on THC, what challenges would that bring not only to the industry but also to reduce as much as possible the black market?
OGI: We have seen the House reject the proposed THC limit and I think it was the right move on their part. Where it ends up in the ping-pong between the House and the Senate is anyone’s guess. I think a THC limit would limit the legal market’s ability to steal market share from the black market.
CCIM: Organigram has been a hot topic lately with respect to merger and acquisition potential. What can you say on that front?
Louis Kyron: CCIM
Greg Engel, CEO: OGI